IL17A and temporal arteritis: Anakinra (IL-1 receptor antagonist), ustekinumab (anti-IL-12/23p40 monoclonal antibody), and secukinumab (anti-IL-17A monoclonal antibody) have demonstrated the effectiveness in the treatment of giant cell arteritis in case reports, case series, and non-controlled cohort studies [39,40,41,42,43].